PARADIGM-2: Two parallel phase I studies of olaparib and radiotherapy or olaparib and radiotherapy plus temozolomide in patients with newly diagnosed glioblastoma, with treatment stratified by MGMT status
oleh: Ben Fulton, Susan C. Short, Allan James, Stefan Nowicki, Catherine McBain, Sarah Jefferies, Caroline Kelly, Jon Stobo, Anna Morris, Aoife Williamson, Anthony J. Chalmers
| Format: | Article |
|---|---|
| Diterbitkan: | Elsevier 2018-01-01 |
Deskripsi
Glioblastoma has a dismal prognosis and molecular targeted agents have failed to improve outcomes to date. PARADIGM-2 is a phase I dose escalation study evaluating olaparib plus radiotherapy ± temozolomide in newly diagnosed glioblastoma, using MGMT methylation status to stratify patients and inform treatment schedules.